Three Times Daily Dosing of UT-15C

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01746485
Recruitment Status : Completed
First Posted : December 11, 2012
Last Update Posted : December 12, 2012
Information provided by (Responsible Party):
United Therapeutics

Brief Summary:
To evaluate the pharmacokinetics of three-times daily dosing of UT-15C in healthy volunteers

Condition or disease Intervention/treatment Phase
Healthy Drug: UT-15C Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: A PK Evaluation of Three Times Daily Dosing of UT-15C SR Tablets in Healthy Subjects
Study Start Date : July 2012
Actual Primary Completion Date : July 2012
Actual Study Completion Date : July 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: UT-15C Drug: UT-15C
Other Names:
  • treprostinil diethanolamine
  • treprostinil diolamine
  • UT-15C SR

Primary Outcome Measures :
  1. Area under the curve (AUC) from 0-24hrs after 6 days of TID dosing. [ Time Frame: 6 days ]
    Cmax, tmax, AUC(0-6), AUC(0-24), AUC(6-12), AUC(12-24) and t1/2

Secondary Outcome Measures :
  1. PK profile of UT-15C after a single 0.5mg dose on Day 1 [ Time Frame: 1 day ]
    Day 1: Cmax, tmax, AUC(0-6), AUC(0-24), AUC(0-t), AUC(0-inf), and t1/2

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
  • Healthy male and female subjects
  • aged 18-55 years of age;
  • weight between 50 and 100 kg, with a body mass index (BMI) between 19.0 and 29.9 kg/m2, inclusive for female subjects and
  • weight between 50 and 120 kg, with a BMI between 19.0 and 32.0 kg/m², inclusive for male subjects.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01746485

United States, Texas
PPD Development
Austin, Texas, United States
Sponsors and Collaborators
United Therapeutics
Principal Investigator: Theresa Pham, MD PPD

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: United Therapeutics Identifier: NCT01746485     History of Changes
Other Study ID Numbers: TDE-DU-102
First Posted: December 11, 2012    Key Record Dates
Last Update Posted: December 12, 2012
Last Verified: December 2012

Keywords provided by United Therapeutics:

Additional relevant MeSH terms:
Antihypertensive Agents